copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Edwards Lifesciences Corp - Edwards Lifesciences Board Approves New . . . Board Also Adopts Majority Voting for Directors and Appoints Paul Redmond as Corporate Officer IRVINE, Calif , Sept 18, 2007 - Edwards Lifesciences Corporation (NYSE: EW), a world leader in the products and technologies to treat advanced cardiovascular disease, announced today that its board of directors has authorized an additional share repurchase program to acquire up to $250 million of
Edwards Lifesciences Corp - Edwards Lifesciences to Expand Its . . . SALT LAKE CITY, UT, October 08, 2009 - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today that in anticipation of future growth, the company will be developing a new state-of-the-art manufacturing facility in Draper, Utah, which will enable it to significantly expand its manufacturing and RD capability "Our
Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA . . . The THV is intended to be implanted in a native annulus size range associated with the three-dimensional area of the aortic annulus measured at the basal ring during systole Sizing recommendations for implanting the Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA transcatheter heart valves in a native annulus are provided in the table below:
Edwards EVOQUE Tricuspid Valve Replacement System • Edwards EVOQUE Tricuspid Delivery System (Figure 2) The delivery system has an outer diameter of 28 F and is intended to deliver the EVOQUE valve in the crimped position via the transfemoral venous approach The delivery system handle contains a primary flex knob, secondary flex knob, and depth knob to facilitate EVOQUE valve alignment and positioning in the native valve, and a capsule
Journey Trial Patient | Edwards Lifesciences The JOURNEY trial will evaluate the safety and effectiveness of the investigational J-Valve TF transcatheter aortic valve replacement (TAVR-AR) system for the treatment of symptomatic, severe aortic regurgitation in patients who are at high surgical risk for valve replacement by open heart surgery Contact our Patient Support Center to find a participating hospital near you
Edwards Lifesciences Announces Organizational Changes IRVINE, Calif , Feb 18, 2008 - Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, today announced the company's strengthened alignment into a business unit organizational structure, along with the planned departure in the middle of 2008 of corporate officers Anita B Bessler, Stuart L Foster, and Alex Martin "To
Sapien M3 | Edwards Lifesciences Trial objective Establish the safety and effectiveness of the SAPIEN M3 system in subjects with symptomatic, at least 3+ MR for whom commercially available surgical or transcatheter treatment options are deemed unsuitable due to clinical, anatomical, or technical considerations Primary endpoint Non-hierarchical composite of death heart failure rehospitalization at 1 year Secondary
INSPIRIS RESILIA Aortic Valve, Model 11500A - Edwards Lifesciences 1 1 Device Description The INSPIRIS RESILIA aortic valve, model 11500A, is a stented trileaflet valve comprised of RESILIA bovine pericardial tissue that is mounted on a flexible frame The valve is stored under dry packaging conditions and consequently does not require rinsing prior to implantation The valve is available in sizes 19, 21, 23, 25, 27, and 29 mm See Table 1 for nominal dimensions